Nan Fung Trinity HK Ltd. Buys Shares of 463,654 Climb Bio, Inc. $CLYM

Nan Fung Trinity HK Ltd. purchased a new position in Climb Bio, Inc. (NASDAQ:CLYM) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 463,654 shares of the company’s stock, valued at approximately $575,000. Nan Fung Trinity HK Ltd. owned approximately 0.69% of Climb Bio at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. RA Capital Management L.P. bought a new stake in Climb Bio during the first quarter valued at about $38,332,000. Affinity Asset Advisors LLC purchased a new stake in Climb Bio during the first quarter valued at approximately $1,830,000. Allostery Investments LP acquired a new stake in Climb Bio in the first quarter valued at approximately $299,000. Persistent Asset Partners Ltd purchased a new position in Climb Bio in the first quarter worth $178,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Climb Bio during the second quarter worth $159,000. 69.76% of the stock is currently owned by hedge funds and other institutional investors.

Climb Bio Price Performance

CLYM stock opened at $1.90 on Wednesday. The company has a market capitalization of $129.54 million, a P/E ratio of -2.50 and a beta of -0.06. Climb Bio, Inc. has a 12 month low of $1.05 and a 12 month high of $4.11. The firm’s fifty day simple moving average is $2.07 and its 200-day simple moving average is $1.68.

Climb Bio (NASDAQ:CLYM) last issued its earnings results on Thursday, November 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.03). As a group, sell-side analysts forecast that Climb Bio, Inc. will post -1.57 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CLYM. Weiss Ratings reissued a “sell (d-)” rating on shares of Climb Bio in a research report on Wednesday, October 8th. HC Wainwright began coverage on Climb Bio in a report on Monday, October 13th. They issued a “buy” rating and a $9.00 price target for the company. BTIG Research restated a “buy” rating and set a $8.00 price target on shares of Climb Bio in a research note on Thursday, October 16th. William Blair assumed coverage on shares of Climb Bio in a research note on Thursday, October 16th. They set an “outperform” rating on the stock. Finally, Robert W. Baird assumed coverage on shares of Climb Bio in a report on Friday, August 15th. They set an “outperform” rating and a $9.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $9.20.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.